Alkermes (ALKS) Cost of Revenue (2010 - 2026)
Alkermes (ALKS) posted quarterly Cost of Revenue of $98.1 million for Q2 2026, up 98.37% year-over-year from $49.5 million in Q2 2025, and up 59.33% quarter-over-quarter from $61.6 million in Q1 2026.
Alkermes (ALKS) Cost of Revenue (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cost of Revenue for 17 consecutive years, with $98.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cost of Revenue rose 98.37% year-over-year to $98.1 million; the TTM figure through Jun 2026 stood at $257.5 million (up 15.02% YoY), while the FY2025 annual figure was $196.5 million, down 19.92% from the prior year.
- Cost of Revenue advanced to $98.1 million in Q2 2026 per ALKS's latest filing, from $61.6 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $98.1 million in Q2 2026 and bottomed at $46.2 million in Q4 2025.
- Historically, Cost of Revenue has averaged $59.6 million across 5 years, with a median of $58.5 million in 2022.
- Annual changes were most pronounced in 2025 — Cost of Revenue retreated 25.61% — and 2026, when it jumped 98.37%.
- Alkermes' Cost of Revenue stood at $53.9 million in 2022, then surged by 30.05% to $70.1 million in 2023, then slipped by 11.42% to $62.1 million in 2024, then declined by 25.61% to $46.2 million in 2025, then soared by 112.32% to $98.1 million in 2026.
- Business Quant data shows ALKS's Cost of Revenue at $98.1 million in Q2 2026, $61.6 million in Q1 2026, and $46.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 98.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.11 Mn |
| Jun 30, 2026 | 98.11 Mn |
| Mar 31, 2026 | 61.58 Mn |
| Mar 31, 2026 | 61.58 Mn |
| Dec 31, 2025 | 46.21 Mn |
| Dec 31, 2025 | 46.21 Mn |
| Sep 30, 2025 | 51.59 Mn |
| Sep 30, 2025 | 51.59 Mn |
| Jun 30, 2025 | 49.46 Mn |
| Jun 30, 2025 | 49.46 Mn |
| Mar 31, 2025 | 49.20 Mn |
| Mar 31, 2025 | 49.20 Mn |
| Dec 31, 2024 | 62.12 Mn |
| Dec 31, 2024 | 62.12 Mn |
| Sep 30, 2024 | 63.10 Mn |
| Sep 30, 2024 | 63.10 Mn |
| Jun 30, 2024 | 61.47 Mn |
| Jun 30, 2024 | 61.47 Mn |
| Mar 31, 2024 | 58.64 Mn |
| Mar 31, 2024 | 58.64 Mn |